Directory

Discover detailed profiles of PoC companies.

BioMatz Inc.

AI-Designed Microbial Consortia Platform for Human Health and Sustainable Agriculture

Specialization

AI Microbiome Engineering Synthetic Biology

Keywords

Defined Microbial Consortia
Live Biotherapeutic Product

BioMatz (BioMH) develops AI-powered microbial consortia for both therapeutic and environmental applications, integrating biotechnology and artificial intelligence to design optimal microbial communities.
Their proprietary BASyMCo (Bespoke Assembly of Synthetic Microbial Consortia) platform uses multi-omics data and AI modeling to identify microbial combinations that improve gut health, metabolic function, and crop productivity.
Applicable to next-generation Live Biotherapeutic Products (LBPs) and sustainable smart-farming biostimulants, BioMatz bridges microbiome science and industrial scalability.

(1) Owned Technology

BASyMCo Platform:
- Integrates microbial Bank–Lab–Solver system
- Explainable AI enables transparent selection of synergistic microbial groups.
- Designs dual-modulation consortia — promoting beneficial bacteria while suppressing harmful ones.
- Enables cost-effective, rapid development of disease- or crop-specific microbiome solutions.

(2) Applied Products

Human Microbiome: Anti-Obesity LBP
- BASyMCo-designed consortia significantly reduced liver fat accumulation and improved gut barrier function in high-fat diet mouse models.
- Confirmed reductions in oxidative stress, serum LPS, and improvements in tight junction proteins (ZO-1, Occludin).
Pathogen Defense: Anti-Staphylococcus aureus LBP
- Two-strain consortium achieved 94.2% reduction in S. aureus growth after 24-hour co-culture testing.
Smart-Farming Biostimulant
- Designed microbial consortia enhanced plant growth-promoting bacteria (PGPB) activity and yield.
- In hydroponic tomato cultivation, stem growth increased by 27.5% and root growth by 10%.
- Pilot-scale greenhouse (1,500 m²) in operation for tomato efficacy and microbial database optimization.

(1) Problem Definition / Development Background

Most existing LBPs use single strains with inconsistent clinical results and low intestinal stability.
Agricultural biostimulants often depend on uncertain microbial compositions, limiting reproducibility.

(2) Value Proposition / Solution

BioMatz’s BASyMCo platform rationally designs defined microbial consortia with measurable efficacy and scalability.
Combines AI-guided microbial interaction modeling and multi-omics data learning for targeted functionality.
Enables the creation of standardized, culturable, and mass-producible microbiome solutions.

AI Advantage: First-in-class explainable AI for microbiome design based on microbial interaction networks.
Scalability: Proof-of-concept validated across human, animal, and plant ecosystems.
Speed & Cost: Reduces development time and cost by >70% compared to empirical screening.
Sustainability: Applies the same AI engine to healthcare and agri-biotech, enabling circular biomanufacturing.

Pipeline:
- Human Health: Anti-obesity, anti-infection LBPs in preclinical validation.
- AgriTech: PGPB consortia in greenhouse pilot stage (tomato).
Strategic Partners: National research institutions, agricultural cooperatives, and biopharma companies.
Target Milestones:
- 2025: Complete LBP preclinical data packages.
- 2026: Initiate first-in-human trials and commercialize microbial biostimulants.

(1) PoC Progress

Developed multi-omics data pipelines for microbial communities applicable to human and plant ecosystems.
Demonstrated anti-obesity efficacy in mouse model and anti-bacterial activity validated through co-culture analysis.
Pilot greenhouse cultivation projects underway (2024–2025) to validate yield impact and database modeling.

(2) Global Expansion

Europe & U.S.: Targeting microbiome therapeutics partners for LBP co-development.
Asia-Pacific: Expanding smart-farming biostimulant distribution via local partnerships.
Building a cross-domain AI microbiome consortium connecting human health and agriculture.